Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295982 | 1.00 | LMNA (0.36) | LMNANOS3NOS1NOS2CCR4 | |
| SCHEMBL1731975 | 0.83 | HTT (0.39) | LMNACCR4HTTRECQLPIK3CA | |
| SCHEMBL29395867 | 0.83 | HTT (0.39) | LMNACCR4HTTRECQLPIK3CA | |
| SCHEMBL13745097 | 0.80 | PIK3CA (0.35) | LMNANOS3NOS1NOS2HTT | |
| SCHEMBL15233567 | 0.79 | CCR4 (0.38) | LMNACCR4HTTRECQLPIK3CA | |
| SCHEMBL10304917 | 0.79 | PIK3CA (0.37) | LMNANOS3NOS1NOS2PIK3CA | |
| SCHEMBL68083 | 0.78 | CCR4 (0.43) | CCR4HTTEDNRA | |
| SCHEMBL15624611 | 0.78 | USP7 (0.38) | LMNAPIK3CAMAPTCASP1AURKA | |
| SCHEMBL29364914 | 0.78 | CCR4 (0.43) | CCR4HTTEDNRA | |
| SCHEMBL11222657 | 0.78 | SIRT6 (0.37) | LMNAHTTRECQLPIK3CAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571199-B1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4458826-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | Alchemedicine, Inc. (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-118284605-A | Compounds, angiotensin II type 1 receptor antagonists and pharmaceutical compositions | 亚克医药株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| US-5861401-A | TREATMENT OF CONGESTIVE HEART FAILURE | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| EP-0889038-A1 | Process for the preparation of alkoxy-or aryloxypyrazine derivatives | LONZA AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0820993-A2 | Process for the production of 3-alkoxy-5-alkylpyrazin-2-amines | LONZA AG (CH) | 1998-01-28 | — | — | EP | disclosed |
| US-5668137-A | N-heterocyclic sulfonamides having endothelin receptor activity | ZENECA LTD. (GB) | 1997-09-16 | — | — | US | disclosed |
| EP-0752986-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1997-01-15 | — | — | EP | disclosed |
| EP-0749964-A1 | N-Heterocyclyl biphenyl sulfonamides | ZENECA LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995026957-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | EDNRA, EDNRB, ECE1 | LMNA 2210/4885NOS3 597/4885NOS1 495/4885 |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | LMNA 4884/4885NOS3 3919/4885NOS1 4119/4885 |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN6, PTPN1 | LMNA 4789/4885NOS3 3246/4885NOS1 3681/4885 |
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | AGTR1, AGTR2, ADRB1 | LMNA 3881/4885NOS3 4421/4885NOS1 3248/4885 |
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | REN, BDKRB2, BDKRB1 | LMNA 2702/4885NOS3 1636/4885NOS1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.